Is there opportunity for approaches utilizing polypharmacology, multiple target modulation, and phenotype driven drug development in the current drug discovery environment? The convention of hit-to-lead small molecule inhibitor development seems to screech to a halt in the clinic and may be on the way out conceptually, and immuno-oncology is a life saver in the literal sense, but isn't positioned to solve every cancer-related health concern.
I'm in the process of submitting a whole stack of proposals for development of a novel drug platform, and the only approach I seem to have for funding in a PI role as an under-30 with only a B.S. (granted, with a team of experienced academic collaborators) is through small business applications through the NIH. Any advice for someone in my situation, or similar "outsiders" with potential and ambition, on how to break into the drug development field?
lowearthorbit2 karma
Hello, and thanks for the AMA!
Is there opportunity for approaches utilizing polypharmacology, multiple target modulation, and phenotype driven drug development in the current drug discovery environment? The convention of hit-to-lead small molecule inhibitor development seems to screech to a halt in the clinic and may be on the way out conceptually, and immuno-oncology is a life saver in the literal sense, but isn't positioned to solve every cancer-related health concern.
I'm in the process of submitting a whole stack of proposals for development of a novel drug platform, and the only approach I seem to have for funding in a PI role as an under-30 with only a B.S. (granted, with a team of experienced academic collaborators) is through small business applications through the NIH. Any advice for someone in my situation, or similar "outsiders" with potential and ambition, on how to break into the drug development field?
Any comments you have are greatly appreciated.
View HistoryShare Link